Kininogen-1 light chain,高分子量激肽原轻链抗体-抗体-抗体-生物在线
Kininogen-1 light chain,高分子量激肽原轻链抗体

Kininogen-1 light chain,高分子量激肽原轻链抗体

商家询价

产品名称: Kininogen-1 light chain,高分子量激肽原轻链抗体

英文名称: Anti-Kininogen-1 light chain antibody

产品编号: HZ-9504R

产品价格: null

产品产地: 中国/美国

品牌商标: HZbscience

更新时间: 2023-08-17T10:24:20

使用范围: WB,ELISA,IHC-P,IHC-F,IF

上海沪震实业有限公司
  • 联系人 : 鲍丽雯
  • 地址 : 上海市闵行区闵北路88弄1-30号第22幢AQ136室
  • 邮编 : 200612
  • 所在区域 : 上海
  • 电话 : 139****0749
  • 传真 : 021-60345367
  • 邮箱 : www.shzbio.net

Kininogen-1 light chain,高分子量激肽原轻链抗体

产品编号HZ-9504R
英文名称Kininogen-1 light chain
中文名称高分子量激肽原轻链抗体
别 名HMW Kininogen; Alpha 2 thiol proteinase inhibitor; HMW Kininogen light Chain; Alpha-2-thiol proteinase inhibitor; Fitzgerald factor; High molecular weight kininogen; HMWK; Ile-Ser-Bradykinin; Kallidin I; Kallidin II; Kininogen 1; KNG1; KNG1_HUMAN; Williams-Fitzgerald-Flaujeac factor; Kininogen-1.
说 明 书0.1ml 0.2ml
研究领域心血管 细胞生物 免疫学
抗体来源Rabbit
克隆类型Polyclonal
交叉反应 Human, Mouse, Rat, Dog, Rabbit, Sheep,
Kininogen-1 light chain,高分子量激肽原轻链抗体产品应用WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:50-200 (石蜡切片需做抗原修复)
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量28/70kDa
细胞定位分泌型蛋白
性 状Lyophilized or Liquid
浓 度1mg/1ml
免 疫 原KLH conjugated synthetic peptide derived from human HMW Kininogen-1 light chain
亚 型IgG
纯化方法affinity purified by Protein A
储 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
保存条件Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
Kininogen-1 light chain,高分子量激肽原轻链抗体PubMedPubMed
产品介绍background:
This gene uses alternative splicing to generate two different proteins- high molecular weight kininogen (HMWK) and low molecular weight kininogen (LMWK). HMWK is essential for blood coagulation and assembly of the kallikrein-kinin system. Also, bradykinin, a peptide causing numerous physiological effects, is released from HMWK. In contrast to HMWK, LMWK is not involved in blood coagulation. Three transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Oct 2009].

Function:
Kininogens are inhibitors of thiol proteases; (2) HMW-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII; (3) HMW-kininogen inhibits the thrombin- and plasmin-induced aggregation of thrombocytes; (4) the active peptide bradykinin that is released from HMW-kininogen shows a variety of physiological effects: (4A) influence in smooth muscle contraction, (4B) induction of hypotension, (4C) natriuresis and diuresis, (4D) decrease in blood glucose level, (4E) it is a mediator of inflammation and causes (4E1) increase in vascular permeability, (4E2) stimulation of nociceptors (4E3) release of other mediators of inflammation (e.g. prostaglandins), (4F) it has a cardioprotective effect (directly via bradykinin action, indirectly via endothelium-derived relaxing factor action); (5) LMW-kininogen inhibits the aggregation of thrombocytes; (6) LMW-kininogen is in contrast to HMW-kininogen not involved in blood clotting.

Subcellular Location:
Secreted, extracellular space.

Kininogen-1 light chain,高分子量激肽原轻链抗体Tissue Specificity:
Secreted in plasma. T-kinin is detected in malignant ovarian, colon and breast carcinomas, but not in benign tumors.

Post-translational modifications:
Bradykinin is released from kininogen by plasma kallikrein.
Hydroxylation of Pro-383 occurs prior to the release of bradykinin.
Phosphorylation sites are present in the extracellular medium.
N- and O-glycosylated. O-glycosylated with core 1 or possibly core 8 glycans.

DISEASE:
Defects in KNG1 are the cause of high molecular weight kininogen deficiency (HMWK deficiency) [MIM:228960]. HMWK deficiency is an autosomal recessive coagulation defect. Patients with HWMK deficiency do not have a hemorrhagic tendency, but they exhibit abnormal surface-mediated activation of fibrinolysis.

Similarity:
Contains 3 cystatin kininogen-type domains.

Gene ID:
3827

Database links:
Entrez Gene: 3827 Human
Omim: 612358 Human
SwissProt: P01042 Human
Unigene: 77741 Human

Kininogen-1 light chain,高分子量激肽原轻链抗体Important Note:
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.